TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06180460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM
Description: The CALM intervention is a supportive-expressive therapy that is administered by CALM trained clinicians in a particular style.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual includes a list of local / national resources (e.g., psychologist, social worker, or other mental health providers) if an individual chooses to seek treatment for the distress they are experiencing.
Study: NCT06146114

Intervention type: DIAGNOSTIC_TEST
Intervention: Collect HER2 expression in prostate cancer patients
Description: HER2 testing and disease information collection for patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023
Study: NCT06188832

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucomannan, inulin, and psyllium
Description: the subjects recieved fiber supplement containing glucomannan, inulin, and psyllium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the subjects recieved placebo
Study: NCT05570981

Intervention type: DIAGNOSTIC_TEST
Intervention: Laryngeal sensitivity testing
Description: Direct stimulation of the laryngeal adductor reflex, measurement of laryngeal EMG and our capability to assess functional laryngeal response to an inhalational challenge with laryngoscopic techniques.

Intervention type: DIAGNOSTIC_TEST
Intervention: Laryngeal sensitivity testing
Description: Direct stimulation of the laryngeal adductor reflex, measurement of laryngeal EMG and our capability to assess functional laryngeal response to an inhalational challenge with laryngoscopic techniques.
Study: NCT00068991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV skills training program and questionnaire
Description: Two-hour weekly skills training sessions followed by evaluation questionnaire

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-level stigma reduction program
Description: Two-hour training sessions focusing on anti-stigma and anti-discrimination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cross-sectional survey
Description: Survey evaluation of community attitudes towards HIV
Study: NCT04438187

Intervention type: OTHER
Group type: OTHER
Intervention: antimicrobial initiation
Description: antimicrobial initiation based on protocol assignment.

Intervention type: OTHER
Group type: OTHER
Intervention: antimicrobial initiation
Description: antimicrobial initiation based on protocol assignment.
Study: NCT04605913

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Modified GCN+TTF treatment
Description: The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). One cycle consists of 28 days including 2 chemotherapy treatments (same regimen studied in the PAXG trial: Reni BJC 2016 without capecitabine). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1.
Study: NCT04729712

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anaesthesiologist-administered ultrasound guided Erector Spinae block with catheter insertion
Description: Erector Spinae block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the erector spinae plane prior to surgical incision. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgeon-administered video-assisted Paravertebral block with catheter insertion
Description: Paravertebral block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the paravertebral space after the thoracoscopic ports have been sited. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
Study: NCT06636370

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced mammography (CEM)
Description: This intervention group receives supplemental screening with CEM after a negative screening result within the Dutch National Breast Cancer Screening program

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abbreviated MRI (AB-MRI)
Description: This intervention group receives supplemental screening with AB-MRI after a negative screening result within the Dutch National Breast Cancer Screening program
Study: NCT05289648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib oral capsule
Description: Low dose oral niraparib capsules (2 x 100 mg) once a day for 28 days
Study: NCT05115123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 60 mg duloxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04710862

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing training without a device
Description: Breathing training without a mouth device

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing training with a device
Description: Breathing training with a mouth device
Study: NCT04539704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnet and sham
Description: In same subject some areas will have magnet and others will have sham

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: magnet and sham
Description: In same subject some areas will have magnet and others will have sham
Study: NCT06212583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: niraparib/abiraterone acetate
Description: Patients on Arm 2 to receive drug for 6 months

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic ablative radiation therapy (SABR)
Description: Both arms will receive SABR

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic ablative radiation therapy (SABR)
Description: Both arms will receive SABR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Description: All ADT is provided as best prescribed for patient per their medical oncologist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Description: All ADT is provided as best prescribed for patient per their medical oncologist.
Study: NCT06219551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile messages via What's App
Description: The information article that was prepared by taking the opinions of academics experienced in adult education, and were prepared as a video by the primary Rheumatologist who performs the randomization and will be shared in the Whatsapp group as information. Additionally, information will be provided once a week regarding the appointment date of the smoking cessation clinic.
Study: NCT05245513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Community Center Linkage (RCCL)
Description: A certified recovery coach will meet with participants to educate them on recovery support services, including recovery community centers, and link them to a recovery community center, with the aid of a facilitated connection to a volunteer recovery community center member (e.g., calling a standby peer, scheduling a meet-up at the center). The coach will also provide the participant with a brochure of recovery support resources.
Study: NCT06219551

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile messages via What's App
Description: The information article that was prepared by taking the opinions of academics experienced in adult education, and were prepared as a video by the primary Rheumatologist who performs the randomization and will be shared in the Whatsapp group as information. Additionally, information will be provided once a week regarding the appointment date of the smoking cessation clinic.
Study: NCT05245513

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition (CC)
Description: A certified recovery coach will meet with participants to educate them on recovery support services more broadly, including recovery community centers, and will provide them with a brochure of recovery support resources.
Study: NCT04765592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WeFlow-Arch Modeler Embedded Branch Stent Graft System
Description: The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
Study: NCT04524338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Brain Stimulation Devices attached to scalp
Study: NCT05367531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector
Description: For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Injector
Description: For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled
Description: For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience).
Study: NCT05649176

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet without soy
Description: The diet is designed to moderate the blood glucose response with a similar macronutrient composition as the experimental diet but does not contain soy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet with soy
Description: The diet is designed to moderate the blood glucose response with a similar macronutrient composition as the comparator diet but contains soy.
Study: NCT06337201

Intervention type: DEVICE
Intervention: Test of the application Min Memoria
Description: Focus group interviews will be conducted to reach healthcare professionals' experiences using a written life story in daily care. Then, the information from the written life story will be transferred to the application, and the healthcare professionals will test a digital life story (the application) in daily care instead. Observation studies will be conducted to observe the use of the digital life story. What can be seen in the communication and the interaction, and in what situations is the digital life story used?
Study: NCT05952414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-efficacy-based interventions
Description: The intervention aims at increasing self-efficacy and consists of Cognitive Behavioural Therapy (CBT)-based exercises related to sources of self-efficacy beliefs: 1) mastery experiences, 2) vicarious experiences, 3) verbal persuasions, and 4) emotional and physiological states.
Study: NCT04988373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified aligner appliance
Description: Patients will be treated using a single aligner appliance with NiTi Springs in order to align their crowding teeth.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional fixed appliance
Description: Patients will undergo typical orthodontic treatment using an MBT-prescription of metallic brackets.
Study: NCT06159478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib 15 MG
Description: Binimetinib 45mg is orally administered twice daily.
Study: NCT06487403

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care external beam radiotherapy (single integrated boost)
Description: 70Gy in 35 fractions, 56 Gy in 35 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care external beam radiotherapy (two-phase treatment)
Description: 70Gy in 35 fractions, delayed 40 Gy in 20 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.
Study: NCT06559709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive 3 meals per day and snacks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Meet with dietitian

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05069038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Palbociclib at a dose of 125 mg should be taken by mouth with food on 21 days on 7 days off schedule (meaning: on Days 1-21of each 28-day cycle). If a subject misses a day's dose entirely, she must be instructed not to make it up the next day but just take her regular dose at the next assigned time. If a subject vomits any time after taking a dose, she must be instructed not to retake the dose but resume subsequent dosing at the next assigned time. If a subject inadvertently takes an extra dose during a day, she must be instructed to not take the next day's dose.
Study: NCT06377189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention arm - Consultation-Liaison (CL) brief psychiatric intervention in primary care settings
Description: The CL brief psychiatric intervention (2 months) in the primary setting will consist of 3 different phases:~1. A direct referral of their PCP to the practice's CL psychiatrist will be held directly after the inclusion of the patient to the intervention arm, by conducting a clinical exchange (by oral or by mail) with the latter.~2. The CL psychiatrist will organize rapidly (in a delay of 1-2 weeks) a first session and will perform 1 to 4 psychiatric sessions, depending on the participant's needs. These sessions will take place in his/her consultation room, located in the referring PCP's practice, and will be completed in less than 2 months. No intervention guide will be provided to perform these sessions.~3. A joint feedback session between the PCP, the participant, and the CL psychiatrist will be organized (2 months after the first psychiatric session), during which the CL psychiatrist will make restitution of his/her proposals, from a biopsychosocial perspective.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm - Treatment As Usual (TAU)
Description: PCPs will explain to the participants that they will treat their psychological suffering, by providing the usual care for patients with psychiatric co-morbidities. Treatment as usual (TAU) by the PCP may involve supportive care (psychoeducation, psychotherapeutic support, social interventions, etc.), referral to a mental health provider (psychotherapist, psychiatrist, psychiatric nurse, etc.), treatment with psychotropic drugs, hypnosis, acupuncture, relaxation, etc. So as to facilitate their task, PCPs participating in this study will be provided with a list of mental health workers that they could contact.
Study: NCT04253132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolfenamic Acid
Description: Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolfenamic Acid
Description: Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolfenamic Acid
Description: Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: oral placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: oral placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: oral placebo
Study: NCT04894240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monepantel
Description: Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
Study: NCT04890990

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short videos
Description: Intervention videos will each be of 90-second duration and feature two underage professionals (ages 16) acting as a simulated patient. All videos will focus on an empowered presenter with depression sharing her personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted her in overcoming symptoms of the illness. The actors will include a Black girl and a white girl.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short videos
Description: Intervention videos will each be of 90-second duration and feature two underage professionals (ages 16) acting as a simulated patient. All videos will focus on an empowered presenter with depression sharing her personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted her in overcoming symptoms of the illness. The actors will include a Black girl and a white girl.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short videos
Description: Intervention videos will each be of 90-second duration and feature two underage professionals (ages 16) acting as a simulated patient. All videos will focus on an empowered presenter with depression sharing her personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted her in overcoming symptoms of the illness. The actors will include a Black girl and a white girl.
Study: NCT05702268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-332
Description: Tablet, 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-332
Description: Tablet, 40 mg
Study: NCT05000528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic education
Description: In groups of 5-6, patients will have a one-day therapeutic training session comprising 4 workshops: how to create a sleep agenda; normal sleep; sleep hygiene; medical treatments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Actimetry
Description: once from inclusion for 2 weeks, second for 2 weeks starting 2 weeks after intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actimetry
Description: once from inclusion for 2 weeks, second for 2 weeks starting 2 weeks after intervention
Study: NCT05489705

Intervention type: DRUG
Intervention: Mavacamten
Description: As per product label

Intervention type: DRUG
Intervention: Non-mavacamten symptomatic oHCM therapy
Description: Including Beta-blocker (BB), non-dihydropyridine (non-DHP) calcium channel blocker (CCB) and/or disopyramide as per product label
Study: NCT06475560

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CCE arm
Description: Twice a week, patients will attend the in-hospital clinic in groups of five persons. They will bring their completed FIT sample, questionnaire, and the signed consent form. A project nurse will administer the capsules in the morning, and the patients can leave after. When the capsule investigation is completed, patients must return their belt and receiver to the Department of Surgery, OUH. After a few days, the patient will receive an electronic letter with the results and information regarding upcoming steps. Those with positive findings or an incomplete investigation will be given a new appointment according to the current clinical routine. A second questionnaire will be sent to the patient 2 weeks after the completed procedure.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: OC arm
Description: Patients will start bowel cleansing according to the instructions. They will bring their completed questionnaire and the signed consent form to the scheduled colonoscopy. They will continue to follow the routine clinical setup for outpatient colonoscopy and will only receive, by digital post, after 2 weeks from the procedure, an extra second questionnaire.